These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 9762948)
1. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group. Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948 [TBL] [Abstract][Full Text] [Related]
2. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS; Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645 [TBL] [Abstract][Full Text] [Related]
3. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640 [TBL] [Abstract][Full Text] [Related]
4. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities. Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919 [TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297 [TBL] [Abstract][Full Text] [Related]
7. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. Crawford J; George M Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study. Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905 [TBL] [Abstract][Full Text] [Related]
9. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549 [TBL] [Abstract][Full Text] [Related]
11. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen. Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363 [TBL] [Abstract][Full Text] [Related]
12. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267 [TBL] [Abstract][Full Text] [Related]
13. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer. Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007 [TBL] [Abstract][Full Text] [Related]